International Body Positive Mentor, Arabella S. Ruby, Launches New Fashion Collection Under the Xehar Brand, Arabella by Xehar
Xehar's successful ambassador marketing campaign continues to drive online sales while spreading body positive messages among millennials around the world
PLAYA VISTA, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Today Xehar launches their newest collection Arabella by Xehar, an edgy and contemporary plus size fashion line targeting progressive millennials. High demand for Xehar's custom clothing lines can be seen by the recent collection Laura by Xehar, which sold out in a record 10 days. Xehar has developed a proven method in creating collections inspired by Body Positive Mentors who have a significant social media following.
A photo is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/10d6e5d8-c740-4c41-aa56-2255e6f70ad9
"Customers appreciate authenticity, and we are seeing great results by sharing our products through our Body Positive Mentors," says Hadari Oshri, CEO and founder of Xehar. "We are actively searching for more Body Positive Mentors like Arabella, who are passionate about spreading our #aconfidentyou mission."
In conjunction with the launch, Arabella and Laura are being flown by Xehar to meet with their fans in Los Angeles, where they will be showcasing their custom collections. Xehar is built on the belief that fashion empowers women of all shapes, sizes and backgrounds. To further spread their feel-good fashion, the company is launching their new XeharApp in January of 2018, to help deliver body positive, fashionable outfits at affordable prices.
"There are a lot of things on TV, social media and magazines that pressure us to become someone else and not true to our own happiness," says Arabella S. Ruby, Xehar Body Positive Mentor. "To me, body positive means actually taking time to look in the mirror and smile at what you see."
With Body Positive Mentors from the USA, United Kingdom, Hungary, Canada and Italy, Xehar continues their worldwide search. To learn more or apply visit www.xehar.com/community
About Xehar: Xehar is a fashion-tech company that was founded with a rebellious spirit and a lofty objective: To offer chic clothes at revolutionary prices, using technology and their mobile application to make buying decisions easier, all while building confidence in women through inspiring fashion. Xehar has two main divisions, an online store called the Xehar Marketplace and a mobile application called Xehar App. Learn more at Xehar.com
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Xehar, Inc.
investorrelations@xehar.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Xehar via Globenewswire
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release
WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,
Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse
Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør
Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse
Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er foretaget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag
Forløb af ordinær generalforsamling i Investeringsforeningen ValueInvest Danmark den 19. april 202419.4.2024 11:30:00 CEST | pressemeddelelse
Bestyrelsens beretning Bestyrelsens beretning blev taget til efterretning. Årsrapport, udbytte og bestyrelsesmedlemmernes honorar Årsrapporten for 2023 blev enstemmigt godkendt, herunder bestyrelsens honorar samt forslag om udbetaling af udbytte på 13,60 kr. pr. bevis for andelsklasse A i ValueInvest Global KL, og udbytte på 14,60 kr. pr. bevis for andelsklasse W i ValueInvest Global KL. Udbyttebetalingen til investorerne er foretaget aconto den 5. februar 2024. Forslag fremsat af bestyrelsen Der blev ikke fremsat forslag under dette punkt. Valg til bestyrelsen Bestyrelsen havde indstillet til genvalg af Ole Steffensen, Jens Harck og Bent Erik Carlsen, der enstemmigt blev valgt som medlemmer af bestyrelsen. Valg af revisor EY Godkendt Revisionspartnerselskab blev genvalgt som revisor. Med venlig hilsen Bestyrelsen for Investeringsforeningen ValueInvest Danmark c/o BI Management A/S Bredgade 40 1260 København K